Compared with other PD-1 inhibitors, as penpulimab and PD-1 dissociate more slowly, they have higher receptor occupancy and better cell activity and are recommended for Hodgkin’s lymphoma and non-small cell lung cancer (12). This evidence concerns the gene PDCD1 and Hodgkins lymphoma.